Aeterna Zentaris Gmb News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Aeterna zentaris gmb. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Aeterna Zentaris Gmb Today - Breaking & Trending Today

Aeterna Zentaris : THE BOARD OF DIRECTORS RECOMMENDS A VOTE IN FAVOUR OF ALL PROPOSED RESOLUTIONS - Form 6-K

THE BOARD OF DIRECTORS RECOMMENDS A VOTE IN FAVOUR OF ALL PROPOSED RESOLUTIONS.

YOUR VOTE IS IMPORTANT. PLEASE VOTE TODAY.

May 9, 2023

. | May 23, 2023 ....

United States , Bruxelles Capitale , District Of Columbia , United Kingdom , Seattle University , Georgetown University , Gilles Gagnon , Degussa Pensionskasse , Aeterna Zentaris Gmb , Aziyo Biologics , Carolyn Egbert , Peterg Edwards , Nicola Ammer , Leslie Auld , Eckhard Guenther , Carolyns Egbert , Klaus Paulini , Peter Edwards , Eli Lilly , Michael Teifel , Dennis Turpin , Member Of The Audit Committee , Canadian Revenue Agency , International Financial Reporting Standards , Companies Rx , Corporation Or Aeterna Zentaris ,

Aeterna Zentaris Announces the Selection of a Development

–
In collaboration, Aeterna and The University of Sheffield, UK have selected the development candidate AEZS-150, a parathyroid hormone (PTH) fusion polypeptide to start the formal preclinical development for potentially enabling the first in human clinical study.

AEZS-150 has the potential to become a new therapeutic treatment option of primary hypoparathyroidism.
CHARLESTON, S.C., May 06, 2021 (GLOBE NEWSWIRE) Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) through its wholly-owned subsidiary Aeterna Zentaris GmbH, (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that, in consultation with The University of Sheffield, UK (the “University”), Aeterna has selected AEZS-150 as the lead candidate in the Company’s delayed clearance parathyroid hormone fusion polypeptides (DC-PTH) program. Aeterna will now start the ....

United Kingdom , Jenene Thomas , Aeterna Zentaris Gmb , Richardj Ross , Klaus Paulini , United Kingdom The University , Aeterna Zentaris , Company On Twitter , European Commission , University Of Sheffield , Exchange Commission , Aeterna Zentaris Inc , European Union , Novo Nordisk , Aeterna Zentaris Gmbh , Chief Executive Officer , Litigation Reform Act , Annual Report , Common Shares , License Agreements , Nasdaq Aezs , Aeterna Zentaris Inc , C Pth Program , Ezs 150 , Iopharmaceutical Company , Ars Cov 2 ,

Aeterna Zentaris Announces Exclusive License Agreement and

- Company secures next step to continue to build-out pipeline of assets - Company exercised its option to enter into an exclusive license of. ....

United States , United Kingdom , Jenene Thomas , Thomas Rudel , Aeterna Zentaris Gmb , Klaus Paulini , Aeterna Zentaris , Megapharm Ltd , World Health Organization , European Commission , Exchange Commission , Aeterna Zentaris Inc , Wuerzburg The University , Palestinian Authority , European Union , Consilient Health Ltd , Research Agreement , Novo Nordisk , Aeterna Zentaris Gmbh , Julius Maximilians University Wuerzburg , Chief Executive Officer , License Agreement , Licensed Right , Licensed Rights , Consilient Health , Litigation Reform Act ,

Aeterna Zentaris Announces the Selection of a Development

–
In collaboration, Aeterna and The University of Sheffield, UK have selected the development candidate AEZS-150, a parathyroid hormone (PTH) fusion polypeptide to start the formal preclinical development for potentially enabling the first in human clinical study.

AEZS-150 has the potential to become a new therapeutic treatment option of primary hypoparathyroidism.
CHARLESTON, S.C., May 06, 2021 (GLOBE NEWSWIRE) Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) through its wholly-owned subsidiary Aeterna Zentaris GmbH, (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that, in consultation with The University of Sheffield, UK (the “University”), Aeterna has selected AEZS-150 as the lead candidate in the Company’s delayed clearance parathyroid hormone fusion polypeptides (DC-PTH) program. Aeterna will now start the ....

United Kingdom , Richardj Ross , Aeterna Zentaris Gmb , Klaus Paulini , United Kingdom The University , Aeterna Zentaris , Company On Twitter , European Commission , University Of Sheffield , Aeterna Zentaris Inc , Novo Nordisk , Aeterna Zentaris Gmbh , Chief Executive Officer , ஒன்றுபட்டது கிஂக்டம் , ஒன்றுபட்டது கிஂக்டம் தி பல்கலைக்கழகம் , நிறுவனம் ஆன் ட்விட்டர் , ஐரோப்பிய தரகு , பல்கலைக்கழகம் ஆஃப் ஷெஃபீல்ட் , தலைமை நிர்வாகி அதிகாரி ,

Aeterna Zentaris Announces the Selection of a Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism

Aeterna Zentaris Announces the Selection of a Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , Jenene Thomas , Aeterna Zentaris Gmb , Richardj Ross , Klaus Paulini , United Kingdom The University , Aeterna Zentaris , Company On Twitter , European Commission , University Of Sheffield , Exchange Commission , Aeterna Zentaris Inc , European Union , Novo Nordisk , Aeterna Zentaris Gmbh , Chief Executive Officer , Litigation Reform Act , Annual Report , Common Shares , License Agreements , ஒன்றுபட்டது கிஂக்டம் , ஒன்றுபட்டது கிஂக்டம் தி பல்கலைக்கழகம் , நிறுவனம் ஆன் ட்விட்டர் , ஐரோப்பிய தரகு , பல்கலைக்கழகம் ஆஃப் ஷெஃபீல்ட் , பரிமாற்றம் தரகு ,